A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Phase of Trial: Phase III
Latest Information Update: 16 Sep 2017
At a glance
- Drugs Zolmitriptan (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Zosano Pharma
- 26 Jun 2017 According to a Zosano Pharma media release, the company anticipates initiating this trial in the third quarter of 2017.
- 26 Jun 2017 According to a Zosano Pharma media release, the US FDA confirmed the design of this Long-term Safety Study as sufficient to support an NDA filing for M207.
- 06 Mar 2017 New trial record